Anthera Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Anthera Pharmaceuticals, Inc.
EU Business Round-Up: Probi Targets Acquisitions, Oystershell Heads To US, Doetsch Grether Inks Swiss Deal
Probiotics player Probi will use deals and organic growth to double its sales over five years; Belgium's Oysershell strikes deal with Bayer for head-lice brand; and Doetsch Grether acquires Swiss supplements firm Vita.
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.
Developing some of the first coronavirus vaccines and antibody testing kits, venture-backed firms in China have responded fast and partnered actively in the fight against the pandemic, helping them to raise new funds and reach deals. But there have been cautionary tales in other sectors and some investors remain wary.
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, diagnostics companies are rushing to have test kits ready.
- Large Molecule
- Other Names / Subsidiaries
- Alkira Therapeutics, Inc.